Stipple Bio is a biotechnology company harnessing epitope-level precision to create targeted cancer therapies through our proprietary Pointillist Platform, which is designed to identify tumor-specific cell surface epitopes with greater precision. By enabling more selective targeting of cancer cells, the platform aims to improve therapeutic index and unlock targets that have been difficult to address using conventional oncology drug discovery methods. 

We’re advancing our lead candidate ADC STP-100 as an early application of our epitope-targeting approach. 

Founded in 2022 by cancer biology pioneers Aaron Ring (Fred Hutchinson Cancer Center) and Aashish Manglik (University of California, San Francisco), Stipple Bio is grounded in deep expertise across cancer biology, chemical biology and translational science.

Our financing was co-led by RA Capital, a16z Bio+Health and Nextech Invest, and includes participation from existing investors Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), LoLa Capital Partners and GordonMD Global Investments, among others.

Stipple Bio is building a pipeline of next-generation oncology therapeutics with the goal of developing life-changing medicines for cancer patients.

Stipple Bio

Org chart

Teams

Offices